Filtering by:
Cancer UpdatesRisk of Dying from Cancer Continues to Drop at an Accelerated Pace
New 2022 cancer facts and figures show overall improvement, with new milestones for early detection of lung cancer, but with slowing progress for prostate and breast cancer.
Impact Ratings Show Cancer Journal Continues to Outperform
The annual scientific and clinical Journal Impact Factors were released on June 30, and the American Cancer Society’s CA: A Cancer Journal for Clinicians outperformed. The CA impact factor climbed from 292.3 last year to a staggering 508.7 and remains the highest-rated oncology journal in the world.
When Should You Start Getting Screened for Colorectal Cancer?
Regular screening can find colorectal cancer when it is small, hasn’t spread, and might be easier to treat. People at average risk for colorectal cancer begin screening at age 45.
Facts & Figures 2021 Reports Another Record-Breaking 1-Year Drop in Cancer Deaths
Read the Cancer Facts & Figures 2021, for the latest estimates, information and statistics for deaths related to cancer.
Cervical Precancers Drop Since Introduction of HPV Vaccine
A study using data from the Centers for Disease Control and Prevention (CDC) provides evidence that the human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical precancer – lesions that can become cervical cancer.
FDA Approves First Drug for Cancers with a High Tumor Mutational Burden
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug pembrolizumab (Keytruda) to include any cancer with a high tumor mutational burden (TMB-H).
American Cancer Society Updates Guideline for Diet and Physical Activity
The American Cancer Society has updated its guideline on diet and physical activity for cancer prevention. Staying at a healthy weight, staying active throughout life, following a healthy eating pattern, and avoiding or limiting alcohol may greatly reduce a person's lifetime risk of developing or dying from cancer.
FDA Approves Trodelvy (Sacituzumab govitecan-hziy) for Triple Negative Breast Cancer
The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments.